Pharma IQ Members

Pre-Clinical (Discovery and Development)

Find out how to fill up your pipeline and increase innovation. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in early discovery and preclinical research to exchange ideas on best practice and share case studies on innovation within the area.

Contributor: Pharma IQ
Posted: 14/03/2017
Pharma IQ
Pharma IQ presents this A-Z of one of the market's most affordable gene editing technique. Full Article »
Contributor: Diana Davis
Posted: 02/07/2014
Big data is turning up everywhere. In this Process Perspectives podcast, Kaare Buch Petersen, Information Architect in Global IT at Christen Hansen, a Denmark-based supplier of bioscience products to food and health industries, talks about how his company has been using big data in the development of their new products. Editor's note: read a Full Podcast »
Contributor: Regina Au
Posted: 25/10/2016
Regina Au
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells, leading to major side effects such as loss of hair, nausea and vomiting, and risk of infection. Survival was sometimes better, but not much better, depending on the type of cancer and the patient's own genetic and physiological make-up. The big advantage of IO therapies is that they can target specific receptors on the cancer cells and destroy them while leaving the healthy cells alone. This will also help reduce some of the traditional side effects when healthy cells are destroyed. Full Column »
Contributor: Pharma IQ
Posted: 28/02/2017
Pharma IQ
Download this troubleshooting guide to explore the important aspects to consider with compound and biosample management IT issues. Full Whitepaper »